Achyut Healthcar Share Price & Earnings Call Analysis

Financials of Achyut Healthcar

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Achyut Healthcar

Quarterly Results

Quarter-by-quarter operating performance

Dec 2024Mar 2025Sep 2025Dec 2025Mar 2026
Sales +0.000.922.551.574.39
Expenses +0.130.872.471.584.37
Operating Profit-0.130.050.08-0.010.02
OPM %5.43%3.14%-0.64%0.46%
Other Income +0.180.180.110.040.14
Interest0.000.040.000.000.03
Depreciation0.000.060.030.030.08
Profit before tax0.050.130.160.000.05
Tax %20.00%7.69%31.25%0.00%
Net Profit +0.030.120.120.000.06
EPS in Rs0.000.010.010.000.00

Financials of Achyut Healthcar

Profit & Loss

Annual income statement trend

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +0.670.330.274.052.706.143.0511.59
Expenses +0.660.320.264.082.976.123.2511.42
Operating Profit0.010.010.01-0.03-0.270.02-0.200.17
OPM %1.49%3.03%3.70%-0.74%-10.00%0.33%-6.56%1.47%
Other Income +0.000.010.000.140.590.730.920.38
Interest0.000.000.000.000.000.000.000.04
Depreciation0.000.000.000.010.010.010.020.14
Profit before tax0.010.020.010.100.310.740.700.37
Tax %300.00%0.00%0.00%60.00%25.81%32.43%22.86%16.22%
Net Profit +-0.010.010.010.040.230.500.550.32
EPS in Rs-0.020.020.020.000.010.020.020.01
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials of Achyut Healthcar

Balance Sheet

Capital structure and asset base

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital0.250.250.256.749.3516.8323.5624.14
Reserves-0.05-0.040.002.345.1813.937.7410.93
Borrowings +0.000.000.000.000.000.000.000.18
Other Liabilities +0.040.060.250.860.810.191.292.84
Total Liabilities0.240.270.509.9415.3430.9532.5938.09
Fixed Assets +0.000.000.000.030.050.060.031.55
CWIP0.000.000.000.003.499.1618.1927.88
Investments0.000.000.001.701.300.000.000.00
Other Assets +0.240.270.508.2110.5021.7314.378.66
Total Assets0.240.270.509.9415.3430.9532.5938.09

Financials of Achyut Healthcar

Cash Flows

Operating, investing and financing cash movement

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +-0.03-0.020.01-6.96-0.43-0.36-4.06
Cash from Investing Activity +0.000.000.00-1.60-4.81-15.234.69
Cash from Financing Activity +0.000.000.008.795.2115.720.00
Net Cash Flow-0.03-0.020.010.24-0.030.140.62
Free Cash Flow-0.03-0.020.01-6.99-3.75-6.37-14.92
CFO/OP-300%-100%100%23,100%126%-700%1,945%

Financials of Achyut Healthcar

Ratios

Working capital efficiency and return ratios

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days54.48188.03378.5218.0236.5024.37160.3645.66
Inventory Days0.000.00158.7014.2959.593.9624.1615.79
Days Payable380.8741.7855.8712.54143.7144.43
Cash Conversion Cycle54.48188.03156.34-9.4640.2215.7940.8117.02
Working Capital Days76.27210.15216.30603.831,257.221,242.431,169.2091.01
ROCE %9.76%4.35%2.14%2.63%3.27%2.26%1.23%

Others in Pharmaceuticals & Biotechnology this season

  • Novartis India Ltd (Q1 FY27)

    Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…

  • IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)

    Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…

  • Innova Captab Ltd (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharmaceuticals Ltd (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd